Head-To-Head Comparison: Altimmune (NASDAQ:ALT) & Mannatech (NASDAQ:MTEX)

Altimmune (NASDAQ:ALT) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Altimmune and Mannatech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2	1	8	0	2.55
Mannatech	1	0	0	0	1.00

Altimmune currently has a consensus price target of $15.71, indicating a potential upside of 457.24%. Given Altimmune’s stronger consensus rating and higher possible upside, equities analysts plainly believe Altimmune is more favorable than Mannatech.

Earnings & Valuation

This table compares Altimmune and Mannatech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40,000.00	13,710.14	-$88.09 million	($0.93)	-3.03
Mannatech	$108.04 million	0.09	-$15.21 million	($6.71)	-0.76

Mannatech has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Altimmune and Mannatech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Mannatech	-11.97%	-2,383.34%	-40.24%

Volatility and Risk

Altimmune has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Insider & Institutional Ownership

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Altimmune beats Mannatech on 8 of the 14 factors compared between the two stocks.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.